Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in Long-Term trial

NCT ID NCT07003425

Disease control Sponsor: Apogee Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 09, 2026 · Updated 10 times

Summary

This study is for people with moderate-to-severe eczema who have already completed a previous APG777 trial. It aims to see if APG777 is safe and works well over a longer period. Participants will receive injections of the drug every 12 or 24 weeks and be monitored for side effects and skin improvement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
APG777 (an injectable drug)
What this could lead to
If successful, this could confirm APG777 as a safe, long-term treatment option for moderate-to-severe eczema.
What could go wrong
This is an extension study, so results depend on earlier findings. Long-term safety and effectiveness are still being evaluated, and side effects may emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who have completed the Treatment Period in a prior APG777 study and were, in the Investigator's opinion, compliant with the study protocol * Participants who, in the Investigator's opinion, would benefit from long-term treatment with APG777 * Use the same non-prescription non-medicated emollient/moisturizer of their choice from the last day of the Parent Study and throughout the LTE study Exclusion Criteria: * Participants who have developed an AE while participating in the Parent Study, which, in the opinion of the Investigator or of the Medical Monitor, could indicate that continued treatment with APG777 may present an unreasonable risk for the patient * Participants who terminated early from the Parent Study or permanently discontinued the study drug during the Parent Study * Use of any of the prohibited medications from Screening Visit (Visit 1) of the LTE study * Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or interfere with study assessments Note: Additional protocol defined Inclusion/Exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    71 sites in 8 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site

    RECRUITING

    Fountain Valley, California, 92708, United States

  • Investigational Site

    RECRUITING

    Los Angeles, California, 90024, United States

  • Investigational Site

    RECRUITING

    Coral Gables, Florida, 33134, United States

  • Investigational Site

    RECRUITING

    Jacksonville, Florida, 32256, United States

  • Investigational Site

    RECRUITING

    Margate, Florida, 33063, United States

  • Investigational Site

    RECRUITING

    Douglasville, Georgia, 30135, United States

  • Investigational Site

    RECRUITING

    Skokie, Illinois, 60077, United States

  • Investigational Site

    RECRUITING

    Bowling Green, Kentucky, 42101, United States

  • Investigational Site

    RECRUITING

    Rockville, Maryland, 20850, United States

  • Investigational Site

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Investigational Site

    RECRUITING

    Troy, Michigan, 48084, United States

  • Investigational Site

    RECRUITING

    New York, New York, 10023, United States

  • Investigational Site

    RECRUITING

    Wilmington, North Carolina, 28403, United States

  • Investigational Site

    RECRUITING

    Boardman, Ohio, 44512, United States

  • Investigational Site

    RECRUITING

    Mason, Ohio, 45040, United States

  • Investigational Site

    RECRUITING

    Portland, Oregon, 97223, United States

  • Investigational Site

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • Investigational Site

    RECRUITING

    Charleston, South Carolina, 29425, United States

  • Investigational Site

    RECRUITING

    Nashville, Tennessee, 37215, United States

  • Investigational Site

    RECRUITING

    Dallas, Texas, 75230, United States

  • Investigational Site

    RECRUITING

    Frisco, Texas, 75235, United States

  • Investigational Site

    RECRUITING

    San Antonio, Texas, 78213, United States

  • Investigational Site

    RECRUITING

    Mill Creek, Washington, 98012, United States

  • Investigational Site

    RECRUITING

    Calgary, Alberta, T2J 7E1, Canada

  • Investigational Site

    RECRUITING

    Calgary, Alberta, T3E 0B2, Canada

  • Investigational Site

    RECRUITING

    Edmonton, Alberta, T5J 3S9, Canada

  • Investigational Site

    RECRUITING

    Vancouver, British Columbia, V5Z 4E8, Canada

  • Investigational Site

    RECRUITING

    Fredericton, Brunswick, E3B 1G9, Canada

  • Investigational Site

    RECRUITING

    Ajax, Ontario, L1S 7K8, Canada

  • Investigational Site

    RECRUITING

    Markham, Ontario, L3P 1X3, Canada

  • Investigational Site

    RECRUITING

    Mississauga, Ontario, L4Y 4C5, Canada

  • Investigational Site

    RECRUITING

    Ottawa, Ontario, K1K 4L2, Canada

  • Investigational Site

    RECRUITING

    Peterborough, Ontario, K9J 5K2, Canada

  • Investigational Site

    RECRUITING

    Toronto, Ontario, M3B 0A7, Canada

  • Investigational Site

    RECRUITING

    Toronto, Ontario, M4E 2Y9, Canada

  • Investigational Site

    RECRUITING

    Toronto, Ontario, M4W 2N4, Canada

  • Investigational Site

    RECRUITING

    Montreal, Quebec, H2X 2V1, Canada

  • Investigational Site

    RECRUITING

    Québec, Quebec, G1V 4X7, Canada

  • Investigational Site

    RECRUITING

    Prague, Prague, 128 00, Czechia

  • Investigational Site

    RECRUITING

    Prague, Prague Motol, 150 06, Czechia

  • Investigational Site

    RECRUITING

    Prague, Vinohrady, 100 34, Czechia

  • Investigational Site

    RECRUITING

    Prague, 100 00, Czechia

  • Investigational Site

    RECRUITING

    Prague, 16000, Czechia

  • Investigational Site

    RECRUITING

    Heidelberg, Baden-Wurttemberg, 69120, Germany

  • Investigational Site

    RECRUITING

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Investigational Site

    RECRUITING

    Augsburg, Bavaria, 86179, Germany

  • Investigational Site

    RECRUITING

    München, Bavaria, 80337, Germany

  • Investigational Site

    RECRUITING

    Blankenfelde-Mahlow, Brandenburg, 15831, Germany

  • Investigational Site

    RECRUITING

    Darmstadt, Hesse, 64283, Germany

  • Investigational Site

    RECRUITING

    Bad Bentheim, Lower Saxony, 48455, Germany

  • Investigational Site

    RECRUITING

    Münster, North Rhine Westfalia, 48149, Germany

  • Investigational Site

    RECRUITING

    Dresden, Saxony, 1307, Germany

  • Investigational Site

    RECRUITING

    Kiel, Schleswig-Holstein, 24105, Germany

  • Investigational Site

    RECRUITING

    Berlin, 10117, Germany

  • Investigational Site

    RECRUITING

    Hamburg, 20354, Germany

  • Investigational Site

    RECRUITING

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Investigational Site

    RECRUITING

    Wroclaw, Lower Silesian Voivodeship, 50-450, Poland

  • Investigational Site

    RECRUITING

    Wroclaw, Lower Silesian Voivodeship, 51-503, Poland

  • Investigational Site

    RECRUITING

    Lublin, Lublin Voivodeship, 20-573, Poland

  • Investigational Site

    RECRUITING

    Warsaw, Masovian Voivodeship, 01-595, Poland

  • Investigational Site

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-482, Poland

  • Investigational Site

    RECRUITING

    Gdansk, Pomeranian Voivodeship, 80-546, Poland

  • Investigational Site

    RECRUITING

    Katowice, Silesian Voivodeship, 40-600, Poland

  • Investigational Site

    RECRUITING

    Sosnowiec, Silesian Voivodeship, 41-218, Poland

  • Investigational Site

    RECRUITING

    Szczecin, West Pomeranian Voivodeship, 71-500, Poland

  • Investigational Site

    RECRUITING

    Krakow, Woj. Małopolskie, 30-727, Poland

  • Investigational Site

    RECRUITING

    Lodz, 90-237, Poland

  • Investigational Site

    RECRUITING

    Santiago de Compostela, A Coruña, 15706, Spain

  • Investigational Site

    RECRUITING

    Las Palmas de Gran Canaria, Canary Islands, 35010, Spain

  • Investigational Site

    RECRUITING

    Madrid, 28006, Spain

  • Investigational Site

    RECRUITING

    Salford, Greater Manchester, M6 8HD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.